Journal of International Oncology››2023,Vol. 50››Issue (8): 508-510.doi:10.3760/cma.j.cn371439-20230120-00097
• 病例报道 •Previous ArticlesNext Articles
Received:2023-01-20Revised:2023-05-24Online:2023-08-08Published:2023-10-24
"
"
"
"
"
| [1] | Nolan E, Lindeman GJ, Visvader JE, et al. Deciphering breast cancer: from biology to the clinic[J].Cell,2023,186(8):1708-1728. DOI:10.1016/j.cell.2023.01.040. pmid:36931265 |
| [2] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660. |
| [3] | Tray N, Adams S, Esteva FJ. Antibody-drug conjugates in triple negative breast cancer[J].Future Oncol,2018,14(25): 2651-2661. DOI:10.2217/fon-2018-0131. pmid:30175620 |
| [4] | 吕玉珠, 毛大华. 精准医学时代背景下三阴性乳腺癌治疗进展[J].医学综述,2021,27(16): 3199-3203. DOI:10.3969/j.issn.1006-2084.2021.16.015. |
| [5] | 中国抗癌协会肿瘤药物临床研究专业委员会, 国家抗肿瘤药物临床应用监测专家委员会, 国家肿瘤质控中心乳腺癌专家委员会, 等. 抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)[J].中国医学前沿杂志(电子版),2021,13(1): 1-15. DOI:10.12037/YXQY.2021.01-01. |
| [6] | Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors[J].Drugs Today (Barc),2019,55(9): 575-585. DOI:10.1358/dot.2019.55.9.3039669. |
| [7] | Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: a comprehensive review[J].Mol Cancer Res,2020,18(1): 3-19. DOI:10.1158/1541-7786.MCR-19-0582. pmid:31659006 |
| [8] | Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors[J].Clin Cancer Res,2015,21(17): 3870-3878. DOI:10.1158/1078-0432.CCR-14-3321. pmid:25944802 |
| [9] | Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J].Oncotarget,2015,6(26): 22496-22512. DOI:10.18632/oncotarget.4318. pmid:26101915 |
| [10] | Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial[J].Ann Oncol,2021,32(6): 746-756. DOI:10.1016/j.annonc.2021.03.005. pmid:33741442 |
| [11] | Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J].N Engl J Med,2019,380(8): 741-751. DOI:10.1056/NEJMoa18 14213. |
| [12] | Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J].N Engl J Med,2021,384(16): 1529-1541. DOI:10.1056/NEJMoa2028485. |
| [13] | Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors[J].J Clin Oncol,2021,39(22): 2474-2485. DOI:10.1200/JCO.20.03489. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
